Education
About Us
Working with TipRanks
Follow Us
PainReform (PRFX)
NASDAQ:PRFX
PRFX Stock Chart & Stats
$1.29
-$0.27(-7.83%)
At close: 4:00 PM EST
$1.29
-$0.27(-7.83%)
Day’s Range― - ―
52-Week Range$1.20 - $16.63
Previous CloseN/A
Volume49.01K
Average Volume (3M)186.11K
Market Cap
$2.50M
Enterprise Value-$380.11K
Total Cash (Recent Filing)$3.48M
Total Debt (Recent Filing)$56.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding2,013,141
10 Day Avg. Volume213,091
30 Day Avg. Volume186,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-0.12
Enterprise Value/Market Cap-0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Product EfficacyPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial NeedsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
PainReform News
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.20 and its highest was $16.63 in the past 12 months.
What is PainReform’s market cap?
PainReform’s market cap is $2.50M.
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is Feb 27, 2026 which is in 129 days.
How were PainReform’s earnings last quarter?
PainReform released its earnings results on Oct 01, 2025. The company reported -$1.091 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.091.
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainReform have?
PainReform has 2,013,141 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
PainReform reported an EPS of -$1.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
Company Description
PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
Evoke Pharma
―
RedHill Biopharma
―
Sunshine Biopharma
―
Ownership Overview
―
Insiders
0.22% Mutual Funds
0.64% Other Institutional Investors
99.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---